IXICO plc

("IXICO" or the "Company")

First contract award from new Imaging Master Vendor Agreement with top 5 global CRO

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a new contract with a value of more than >$750k over 2 years for advanced neuroimaging solutions by a top 5 global Clinical Research Organization ("CRO") to support its sponsor's Phase II Alzheimer's disease clinical trial.

Conducted across 41 investigator sites within the Unites States and Europe, the clinical trial will enrol patients with Mild to Moderate Alzheimer's Disease to evaluate the safety and efficacy of a subcutaneously administered investigational product.

Following the successful completion of the CRO's independent qualification and audit process, a Master Vendor Agreement was executed between the CRO and IXICO in the month of August.  Being selected as a dedicated imaging vendor is expected to significantly enhance IXICO's opportunity to partner with the CRO's client portfolio.

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"IXICO is delighted to work with our new CRO partner to support their sponsor's Alzheimer's disease clinical trial. One of the core elements of our commercial growth strategy has been to establish strong relationships with select therapeutically aligned partner CROs.  This enables greater access to new biopharmaceutical clients and accelerates the adoption of our proprietary neuroimaging technology solutions, at scale.  Our mission is to support our clients in their tireless efforts to bring potential treatments to patients suffering from neurological disorders. This new award reflects the confidence that CROs and sponsors place in IXICO, as their trusted neuroimaging partner for their pivotal CNS studies."

For further information please contact:

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews